HAVCR2 and cholangiocarcinoma: Despite these limitations, there have been various clinical trials in the pipeline harnessing the role of second-generation immunotherapeutic drugs like anti-TIM3, anti-TIGIT, and TGF beta in combination with chemotherapy and anti-PD1 in CCA.